Inhibrx Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Revenue	-	1.63	1.32
Revenue Growth (YoY)	-	24.26%	-
Gross Profit	-	1.63	1.32
Selling, General & Admin	-	24.25	15.04
Research & Development	-	130.13	101.6
Operating Expenses	-	154.38	116.64
Operating Income	-	-152.75	-115.32
Other Expense / Income	-	2.21	-0
Pretax Income	-	-154.96	-115.32
Income Tax	-	0	0
Net Income	-	-154.96	-115.33
Shares Outstanding (Basic)	13	13	-
Free Cash Flow	-	-133.6	-91.5
Free Cash Flow Per Share	-	-9.98	-
Gross Margin	-	100.00%	100.00%
Operating Margin	-	-9348.04%	-8769.81%
Profit Margin	-	-9483.72%	-8769.96%
Free Cash Flow Margin	-	-8176.25%	-6957.95%
EBITDA	-	-152.01	-112.48
EBITDA Margin	-	-9302.63%	-8553.31%
Depreciation & Amortization	-	2.96	2.85
EBIT	-	-154.96	-115.32
EBIT Margin	-	-9483.54%	-8769.73%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).